Candida auris – mycolab.ai

Candida auris: Outbreak, surveillance and epidemiological monitoring in Northern Greece

mycolabadmin

A dangerous fungus called Candida auris caused an outbreak in hospitals in Northern Greece starting in October 2022. This fungus is particularly concerning because it is resistant to many commonly used antifungal drugs, especially fluconazole. Researchers monitored and tracked the outbreak across multiple hospitals, finding that all cases belonged to the same genetic type (Clade I) and were treatable with certain alternative antifungal medications. The study emphasizes the importance of careful laboratory surveillance and coordinated infection control measures to prevent further spread of this serious infection.

Prospective Study on Microbiological Profile of Fungal Isolates and its Antibiogram in a Tertiary care hospital in South India

mycolabadmin

Researchers studied fungal infections in a hospital in South India over one year, examining 62 fungal isolates. They found that Candida auris, a dangerous fungal species, was the most common and had developed resistance to many antifungal drugs. A newer class of antifungal drugs called echinocandins worked best against these infections, highlighting the importance of quick identification of fungal species for proper treatment.

Pyrvinium Pamoate Synergizes with Azoles in vitro and in vivo to Exert Antifungal Efficacy Against Candida auris and Other Candida Species

mycolabadmin

Researchers tested a combination of an old antiparasitic drug called pyrvinium pamoate with common antifungal medications called azoles against dangerous drug-resistant fungal infections. While pyrvinium pamoate alone was not very effective, when combined with azoles it significantly improved the treatment of Candida auris infections. Tests in insect larvae showed that the combination improved survival rates better than using azoles alone, suggesting a promising new treatment approach for serious fungal infections.

Neonatal Invasive Candidiasis: Current Concepts

mycolabadmin

Neonatal invasive candidiasis is a serious fungal infection affecting premature and very low birth weight babies. The types of fungi causing these infections are changing globally, with more resistant strains appearing, especially in lower-income countries. Treatment options are limited by this resistance, making prevention through hygiene and proper hospital practices increasingly important.

Multi-omics Analysis of Experimentally Evolved Candida auris Isolates Reveals Modulation of Sterols, Sphingolipids, and Oxidative Stress in Acquired Amphotericin B Resistance

mycolabadmin

Researchers studied how the fungus Candida auris develops resistance to amphotericin B, an important antifungal drug. By evolving two laboratory strains of this fungus under drug pressure, they discovered two different ways the fungus can become resistant: one through stress management genes, the other through changes in its protective lipids. These findings help explain why some clinical infections with this dangerous fungus are so hard to treat.

Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives

mycolabadmin

This review examines how doctors treat serious fungal infections and the growing problem of fungi becoming resistant to medications. The authors discuss different antifungal drugs, how they work, and why some fungi are becoming harder to treat. They emphasize that controlling fungal resistance requires coordinated efforts across hospitals, farms, and communities, especially since some agricultural pesticides are creating resistant strains that spread to sick patients.

Brown locusts, Locustana pardalina, host fluconazole-resistant Candidozyma (Candida) auris, closely related to Clade III clinical strains

mycolabadmin

Scientists found that brown locusts in South Africa carry a dangerous yeast called Candida auris that is resistant to the antifungal drug fluconazole. This yeast is similar to strains that infect hospital patients and is highly adaptable, surviving extreme temperatures and salt levels found in locust guts. This discovery suggests that insects like locusts could play a role in spreading this emerging fungal pathogen in nature, which has important implications for understanding how dangerous microbes spread between animals and humans.

HIV protease inhibitors restore amphotericin B activity against Candida

mycolabadmin

Researchers discovered that HIV protease inhibitors, medications commonly used to treat HIV, can significantly enhance the effectiveness of amphotericin B, a powerful antifungal drug. When combined, these medications work synergistically to kill the dangerous fungus Candida auris, reduce its ability to form protective biofilms, and lower infection levels. This finding suggests a promising new treatment strategy for multidrug-resistant fungal infections that currently pose a serious global health threat.

Should all hospitalised patients colonised with Candida auris be considered for isolation?

mycolabadmin

Candida auris is a dangerous yeast found in hospitals that can spread quickly between patients and is very difficult to treat. Healthcare experts in the Netherlands have decided that all hospital patients carrying this fungus should be isolated in single rooms, even if their strain is susceptible to antifungal drugs, because the infection can develop resistance quickly and cause serious illness. This strict isolation approach helps prevent outbreaks and protects vulnerable patients from developing life-threatening blood infections.

Caged-hypocrellin mediated photodynamic therapy induces chromatin remodeling and disrupts mitochondrial energy metabolism in multidrug-resistant Candida auris

mycolabadmin

Researchers developed a new photodynamic therapy treatment using a light-activated compound called COP1T-HA to fight drug-resistant Candida auris infections. The therapy works by reorganizing the fungal cell’s genetic material architecture and disrupting energy production in mitochondria, ultimately killing the fungal cells. This approach represents a novel strategy to overcome antibiotic resistance, as it targets multiple cellular processes rather than a single pathway that fungi can easily resist.

Research Keyword: Candida auris